Clinical Trial Update: Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial update for Zirconium-89 labeled Crefmirlimab Berdoxam PET/CT in advanced or metastatic cancers; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Merkel Cell Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Crefmirlimab Berdoxam (Zirconium-89) (crefmirlimab berdoxam)

Snippet

Sponsor: ImaginAb, Inc. | Conditions: Melanoma, Merkel Cell Carcinoma, Unspecified | Phase 2 | Status: ACTIVE_NOT_RECRUITING